Recent Advances in HER2+ Breast Cancer | Supplements And Featured Publications

Dr. Hurvitz on the Findings of DESTINY-Breast01 in HER2+ Metastatic Breast Cancer

January 08, 2020

Sarah A. Hurvitz, MD, medical oncologist, medical director, Clinical Research Unit for University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the findings in the DESTINY-Breast01 trial of patients with HER2-positive metastatic breast cancer.